One of the largest and most recognizable pharmaceutical companies in the world called Gilead today released a special report in which it spoke about the results of testing its new experimental drug called remdesivir in the fight against a new type of coronavirus – and, looking ahead, we can say that these results are really encouraging. The fact is that by initially launching these clinical trials on volunteers from the most significant foci of the disease in the world, specialists were able to achieve significantly more positive results than was expected at the beginning of clinical trials with all the available data.
In total, 397 patients from the so-called focal countries for coronavirus, including the UK, Sweden, China and the USA, took part in the project. They were divided into two groups, one of which received a standard dose of remdesivir in an amount of 200 mg for the first time, with a gradual decrease in dose, and the second – alternative antibiotic drugs. After completing a two-week course of clinical trials, experts found that remdesivir actually has very promising indicators for improving the condition of patients, since more than half already showed absolute signs of health on 10-12 days and were discharged from the medical institution in which they were kept.
Nevertheless, the clinical trials themselves are still far from complete, since the same team of medical specialists is preparing a parallel test using a modified version of this drug – but the first results of this test will only be available after the end of May of this year, so that remains to be expected preliminary report.
Nevertheless, there is no doubt that specialists will sooner or later present new positive surprises regarding their trials and the current pharmacological state of remdesivir – since it is in fact one of the most promising and effective drugs against coronavirus. At this point in time, some other research teams are also seeking to confirm or refute the current study.